How tenofovir disoproxil fumarate can impact on solubility and dissolution rate of efavirenz?

被引:15
|
作者
Bazzo, Giovana Carolina [1 ]
Mostafa, Dina [1 ]
Franca, Maria Terezinha [1 ]
Pezzini, Bianca Ramos [1 ]
Stulzer, Hellen Karine [1 ]
机构
[1] Univ Fed Santa Catarina, Programa Posgrad Farm, Campus Trindade, BR-88040970 Florianopolis, SC, Brazil
关键词
Efavirenz; Tenofovir disoproxil fumarate; Solubility; Dissolution; Eutectic mixture; DRUG-DELIVERY SYSTEM; SOLID FORMS; ENHANCEMENT; CYCLODEXTRIN; MECHANISMS; BEHAVIOR; DESIGN;
D O I
10.1016/j.ijpharm.2019.118597
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Efavirenz (EFZ) and tenofovir disoproxil fumarate (TDF) can be used simultaneously in the treatment of human immunodeficiency virus type1 infection. In this work the impact of TDF, a hydrophilic drug, on the solubility and dissolution rate of EFZ, a poorly water-soluble drug, was evaluated. EFZ/TDF binary mixtures in different molar ratios were prepared. Differential scanning calorimetry (DSC) results indicate the formation of a eutectic mixture, the molar ratio of 65/35 being the eutectic point. It was observed an increase in the EFZ solubility in water and acidic conditions (0.1 N HCl and biorelevant medium), in the presence of TDF. On the other hand, there was a decreasing on EFZ solubility in phosphate buffer pH 6.8, probably influenced by the lower solubility of TDF in this medium. The high solubility of TDF in water and acidic medium may have contributed to improve the solubility of EFZ, as well as the formation of a eutectic mixture, supported by X-ray powder diffraction (XRPD) and Fourier Transform infrared spectroscopy (FTIR) analyses. However, TDF solubility and dissolution rate was not significantly influenced by the presence of EFZ.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection
    Dubrocq, Gueorgui
    Rakhmanina, Natella
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (08) : 773 - 779
  • [42] Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial
    Chen, Jun
    Chen, Rong
    Shen, Yinzhong
    Wei, Hongxia
    Wang, Xicheng
    Zhang, Renfang
    Hu, Zhiliang
    Xie, Ronghui
    Huang, Qiong
    Wang, Jiangrong
    Liu, Li
    Qi, Tangkai
    Wang, Zhenyan
    Song, Wei
    Tang, Yang
    Sun, Jianjun
    Lu, Hongzhou
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 843 - 850
  • [43] Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
    Greaves, Wayne
    Wan, Hong
    Yee, Ka Lai
    Kandala, Bhargava
    Vaddady, Pavan
    Hwang, Carey
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [44] Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz: An Open-Label, Randomized Controlled Trial
    Boontanondha, Patawee
    Nimitphong, Hataikarn
    Musikarat, Suchawadee
    Ragkho, Aschara
    Kiertiburanakul, Sasisopin
    CURRENT HIV RESEARCH, 2020, 18 (01) : 52 - 62
  • [45] Impact of Nanosizing on Solubility and Dissolution Rate of Poorly Soluble Pharmaceuticals
    Murdande, Sharad B.
    Shah, Dhaval A.
    Dave, Rutesh H.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (06) : 2094 - 2102
  • [46] Design of a novel crosslinked HEC-PAA porous hydrogel composite for dissolution rate and solubility enhancement of efavirenz
    Mabrouk, M.
    Chejara, D. R.
    Mulla, J. A. S.
    Badhe, R. V.
    Choonara, Y. E.
    Kumar, P.
    du Toit, L. C.
    Pillay, V.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 490 (1-2) : 429 - 437
  • [47] Development of HIV-1 Drug Resistance Through 144 Weeks in Antiretroviral-Naive Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934
    Margot, Nicolas A.
    Enejosa, Jeff
    Cheng, Andrew K.
    Miller, Michael D.
    McColl, Damian J.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 52 (02) : 209 - 221
  • [48] Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound
    Frank, Kerstin J.
    Westedt, Ulrich
    Rosenblatt, Karin M.
    Holig, Peter
    Rosenberg, Jorg
    Magerlein, Markus
    Brandl, Martin
    Fricker, Gert
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 47 (01) : 16 - 20
  • [49] Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil
    Wlodarski, K.
    Sawicki, W.
    Haber, K.
    Knapik, J.
    Wojnarowska, Z.
    Paluch, M.
    Lepek, P.
    Hawelek, L.
    Tajber, L.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 94 : 106 - 115
  • [50] Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir plus abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
    Tebas, Pablo
    Kumar, Princy
    Hicks, Charles
    Granier, Catherine
    Wynne, Brian
    Min, Sherene
    Pappa, Keith
    AIDS, 2015, 29 (18) : 2459 - 2464